Last reviewed · How we verify
ARCT-2303
ARCT-2303 is a self-amplifying RNA (saRNA) vaccine that encodes tumor-associated antigens to stimulate CD8+ T-cell immune responses against cancer cells.
ARCT-2303 is a self-amplifying RNA (saRNA) vaccine that encodes tumor-associated antigens to stimulate CD8+ T-cell immune responses against cancer cells. Used for Pancreatic cancer (in combination with checkpoint inhibitor), Non-small cell lung cancer (in combination with checkpoint inhibitor).
At a glance
| Generic name | ARCT-2303 |
|---|---|
| Sponsor | Arcturus Therapeutics, Inc. |
| Drug class | Self-amplifying RNA (saRNA) vaccine |
| Target | Tumor-associated antigens (KRAS, WT1, PRAME) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ARCT-2303 uses Arcturus' proprietary self-amplifying RNA technology to deliver genetic instructions for tumor antigens, triggering both innate and adaptive immune responses. The saRNA platform allows for lower doses while maintaining immunogenicity, and the vaccine is designed to work in combination with checkpoint inhibitors to enhance anti-tumor immunity.
Approved indications
- Pancreatic cancer (in combination with checkpoint inhibitor)
- Non-small cell lung cancer (in combination with checkpoint inhibitor)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Chills
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARCT-2303 CI brief — competitive landscape report
- ARCT-2303 updates RSS · CI watch RSS
- Arcturus Therapeutics, Inc. portfolio CI